Bank of New York Mellon Corp Takes Position in ICU Medical, Inc. $ICUI

Key Points

• Bank of New York Mellon acquired 183,945 ICU Medical shares worth approximately $27.0 million, giving it a 0.74% stake. Institutional investors collectively own 96.1% of the company.
• Analysts maintain a generally positive outlook, with ICU Medical receiving a consensus “Moderate Buy” rating and an average price target of $192.80, above its reported share price of $175.10.
• ICU Medical exceeded quarterly expectations, reporting $2.37 in adjusted earnings per share versus the $1.91 consensus and revenue of $547.88 million. However, insiders sold about $3.1 million of stock over the past 90 days.

Bank of New York Mellon Corp bought a new stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 183,945 shares of the medical instruments supplier's stock, valued at approximately $26,966,000. Bank of New York Mellon Corp owned about 0.74% of ICU Medical at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Hilton Head Capital Partners LLC bought a new position in shares of ICU Medical during the fourth quarter valued at about $32,000. Covestor Ltd boosted its holdings in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock valued at $99,000 after acquiring an additional 126 shares in the last quarter. Strs Ohio increased its position in ICU Medical by 60.0% during the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier's stock valued at $114,000 after purchasing an additional 300 shares during the period. Rockefeller Capital Management L.P. increased its position in ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 146 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new position in ICU Medical in the 4th quarter worth $120,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ICUI has been the topic of a number of research analyst reports. Raymond James Financial reiterated a "strong-buy" rating and set a $200.00 target price on shares of ICU Medical in a report on Friday, August 7th. KeyCorp lifted their price target on ICU Medical from $164.00 to $182.00 and gave the company an "overweight" rating in a research report on Tuesday, July 21st. Sanford C. Bernstein cut ICU Medical to a "market perform" rating in a research note on Monday, June 15th. Piper Sandler raised their price objective on ICU Medical from $163.00 to $195.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Finally, Needham & Company LLC upped their target price on shares of ICU Medical from $165.00 to $187.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, ICU Medical has an average rating of "Moderate Buy" and a consensus target price of $192.80.

Insider Transactions at ICU Medical

In other ICU Medical news, Director Elisha W. Finney sold 378 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total transaction of $68,977.44. Following the completion of the sale, the director directly owned 4,871 shares in the company, valued at $888,860.08. The trade was a 7.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Christian B. Voigtlander sold 8,929 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the sale, the chief operating officer directly owned 37,377 shares of the company's stock, valued at $6,837,374.61. The trade was a 19.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 16,974 shares of company stock worth $3,085,844 in the last ninety days. Insiders own 2.10% of the company's stock.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $175.10 on Friday. ICU Medical, Inc. has a fifty-two week low of $112.50 and a fifty-two week high of $192.85. The business has a 50-day simple moving average of $164.64 and a two-hundred day simple moving average of $144.10. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. The firm has a market cap of $4.38 billion, a price-to-earnings ratio of 148.39, a price-to-earnings-growth ratio of 2.21 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business's revenue for the quarter was up .5% on a year-over-year basis. During the same period in the previous year, the business posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, analysts expect that ICU Medical, Inc. will post 7.19 earnings per share for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source